Nothing Special   »   [go: up one dir, main page]

AU1874397A - Hexitol containing oligonucleotides and their use in antisense strategies - Google Patents

Hexitol containing oligonucleotides and their use in antisense strategies

Info

Publication number
AU1874397A
AU1874397A AU18743/97A AU1874397A AU1874397A AU 1874397 A AU1874397 A AU 1874397A AU 18743/97 A AU18743/97 A AU 18743/97A AU 1874397 A AU1874397 A AU 1874397A AU 1874397 A AU1874397 A AU 1874397A
Authority
AU
Australia
Prior art keywords
hexitol
containing oligonucleotides
antisense strategies
antisense
strategies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU18743/97A
Inventor
Piet Andre Maurits Maria Herdewijn
Arthur Albert Edgard Van Aerschot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stichting Rega VZW
Original Assignee
Stichting Rega VZW
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting Rega VZW filed Critical Stichting Rega VZW
Publication of AU1874397A publication Critical patent/AU1874397A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AU18743/97A 1996-02-16 1997-02-14 Hexitol containing oligonucleotides and their use in antisense strategies Abandoned AU1874397A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP96200403 1996-02-16
EP96200403 1996-02-16
EP96201089 1996-04-23
EP96201089 1996-04-23
PCT/EP1997/000762 WO1997030064A1 (en) 1996-02-16 1997-02-14 Hexitol containing oligonucleotides and their use in antisense strategies

Publications (1)

Publication Number Publication Date
AU1874397A true AU1874397A (en) 1997-09-02

Family

ID=26142518

Family Applications (1)

Application Number Title Priority Date Filing Date
AU18743/97A Abandoned AU1874397A (en) 1996-02-16 1997-02-14 Hexitol containing oligonucleotides and their use in antisense strategies

Country Status (2)

Country Link
AU (1) AU1874397A (en)
WO (1) WO1997030064A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
AU2003295387A1 (en) 2002-11-05 2004-06-03 Isis Parmaceuticals, Inc. Modified oligonucleotides for use in rna interference
CA2463719A1 (en) 2003-04-05 2004-10-05 F. Hoffmann-La Roche Ag Nucleotide analogs with six membered rings
WO2004113496A2 (en) 2003-06-20 2004-12-29 Isis Pharmaceuticals, Inc. Double stranded compositions comprising a 3’-endo modified strand for use in gene modulation
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
US20080261905A1 (en) * 2004-11-08 2008-10-23 K.U. Leuven Research And Development Modified Nucleosides for Rna Interference
WO2006116458A2 (en) * 2005-04-26 2006-11-02 Coley Pharmaceutical Gmbh Modified oligoribonucleotide analogs with enhances immunostimulatory activity
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3533873A1 (en) 2011-09-14 2019-09-04 Translate Bio MA, Inc. Multimeric oligonucleotide compounds
WO2013052523A1 (en) 2011-10-03 2013-04-11 modeRNA Therapeutics Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
ES2923757T3 (en) 2011-12-16 2022-09-30 Modernatx Inc Modified mRNA compositions
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
AU2013243953A1 (en) 2012-04-02 2014-10-30 Modernatx, Inc. Modified polynucleotides for the production of nuclear proteins
ES2921623T3 (en) 2012-11-26 2022-08-30 Modernatx Inc terminally modified RNA
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
AU2014315287A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (en) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. POLYNUCLEOTES ENCODING THE RECEPTOR OF LOW DENSITY LIPOPROTEINS
CA2955250A1 (en) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Chimeric polynucleotides
US20170210788A1 (en) 2014-07-23 2017-07-27 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
MA49421A (en) 2017-06-15 2020-04-22 Modernatx Inc RNA FORMULATIONS
US11744801B2 (en) 2017-08-31 2023-09-05 Modernatx, Inc. Methods of making lipid nanoparticles
CN113271926A (en) 2018-09-20 2021-08-17 摩登纳特斯有限公司 Preparation of lipid nanoparticles and methods of administration thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9300058A (en) * 1992-06-18 1994-01-17 Stichting Rega V Z W 1,5-ANHYDROHEXITOL NUCLEOSIDE ANALOGA AND PHARMACEUTICAL USE THEREOF.
US5314893A (en) * 1993-01-25 1994-05-24 Bristol-Myers Squibb Co. Antiviral tetrahydropyrans
EP0777676A1 (en) * 1994-08-17 1997-06-11 Stichting REGA V.Z.W. Sequence-specific binding oligomers for nucleic acids and their use in antisense strategies

Also Published As

Publication number Publication date
WO1997030064A1 (en) 1997-08-21

Similar Documents

Publication Publication Date Title
AU1874397A (en) Hexitol containing oligonucleotides and their use in antisense strategies
EP0710667B8 (en) Modified oligonucleotides, their preparation and their use
AU7069398A (en) Novel compounds and their use in polymerisation
AU2401697A (en) 4,1-benzoxazepines or 4,1-benzothiazepines and their use as squalene synthetase inhibitors
AU6169998A (en) Biocompatible polymers and methods for their use
HK1008995A1 (en) New thrombin inhibitors, their preparation and use
AU7319994A (en) Nucleotide preparation and uses thereof in wound healing
GB9500856D0 (en) Composition and use
AU5259498A (en) Antisense oligonucleotides
AU3979395A (en) DNA sequences and their use
AU3729493A (en) Cyclobutyl antisense oligonucleotides, methods of making and use thereof
AU2544292A (en) Improvements in oligonucleotide primers and probes
AU3384595A (en) Sequence-specific binding oligomers for nucleic acids and their use in antisense strategies
AU7015396A (en) Cyclin e variants and use thereof
AU3634595A (en) Bis-oxazolidines and their use
AU1249299A (en) Chimeric antisense oligonucleotides against tnf-alpha and their uses
GB9518154D0 (en) Oligonucleotides and their use
AU2529799A (en) Benzofuran-4-carboxamides and their therapeutic use
AU2405397A (en) Thienopyridine derivatives and their use
AU3118395A (en) Oligonucleotides and their use
AU2546392A (en) Improvements in oligonucleotide primers and probes
GB9623539D0 (en) Enzymes and their use
AU5554598A (en) Use of endothelin conjugates in therapy, new endothelin conjugates, substances containing them, and processes for producing them
AU9528798A (en) New triplex forming oligonucleotides and their use in anti-hbv
AU6045199A (en) Stomatin-like genes and their use in plants